Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

In an analysis of Medicare's top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation ... beyond well-known names. Despite being considered ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The approval of Libtayo (cemiplimab) in advanced NSCLC is for first-line treatment of patients with 50% or more PD-L1 expression and no EGFR, ALK or ROS1 aberrations, taking the drug into a large ...

President Donald Trump’s promise to impose tariffs on pharmaceutical imports is raising red flags among generic drugmakers ... than manufacturers of brand-name drugs, experts say.

A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent ... along with other pharmaceutical stocks and drug makers, after President Trump said the ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

Hikma Pharmaceuticals (OTCPK:HKMPF) announced on Thursday that it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets, a cancer treatment medication ...

Approximately half of all respondents reported that their facility uses tall man lettering for similar drug names that appear on pharmacy computer drug selection screens, computer-generated ...